Last reviewed · How we verify

placebo/valsartan — Competitive Intelligence Brief

placebo/valsartan (placebo/valsartan) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker (ARB). Area: Cardiovascular.

marketed Angiotensin II receptor blocker (ARB) AT1 receptor (Angiotensin II type 1 receptor) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

placebo/valsartan (placebo/valsartan) — Medical University of Silesia. Valsartan blocks angiotensin II type 1 receptors, reducing vasoconstriction and aldosterone secretion to lower blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
placebo/valsartan TARGET placebo/valsartan Medical University of Silesia marketed Angiotensin II receptor blocker (ARB) AT1 receptor (Angiotensin II type 1 receptor)
Cozzar tablet Cozzar tablet Chong Kun Dang Pharmaceutical marketed Angiotensin II receptor blocker (ARB) AT1 receptor (angiotensin II type 1 receptor)
Low dose losartan Low dose losartan Baker Heart and Diabetes Institute marketed Angiotensin II receptor blocker (ARB) AT1 receptor (Angiotensin II type 1 receptor)
potassium losartan potassium losartan Fifth Affiliated Hospital, Sun Yat-Sen University marketed Angiotensin II receptor blocker (ARB) AT1 receptor (Angiotensin II type 1 receptor)
RAS Inhibitors RAS Inhibitors Shenzhen Second People's Hospital marketed ACE inhibitor or Angiotensin II receptor blocker (ARB) ACE enzyme or Angiotensin II Type 1 receptor (AT1R)
olmesartan medoxomil and a diuretic olmesartan medoxomil and a diuretic Daiichi Sankyo Co., Ltd. marketed Angiotensin II receptor blocker (ARB) + diuretic combination AT1 receptor (angiotensin II type 1 receptor)
Cozaar® Cozaar® Teva Pharmaceuticals USA marketed Angiotensin II receptor blocker (ARB) AT1 receptor (angiotensin II type 1 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker (ARB) class)

  1. Chong Kun Dang Pharmaceutical · 2 drugs in this class
  2. Baker Heart and Diabetes Institute · 2 drugs in this class
  3. Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
  4. Lee's Pharmaceutical Limited · 2 drugs in this class
  5. Bristol-Myers Squibb · 1 drug in this class
  6. Guangdong Provincial People's Hospital · 1 drug in this class
  7. Fifth Affiliated Hospital, Sun Yat-Sen University · 1 drug in this class
  8. Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 1 drug in this class
  9. Bayer · 1 drug in this class
  10. Arbor Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). placebo/valsartan — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-valsartan. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: